Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Capital Expenditures (2016 - 2024)

Historic Capital Expenditures for NovaBay Pharmaceuticals (NBY) over the last 15 years, with Q4 2024 value amounting to $4000.0.

  • NovaBay Pharmaceuticals' Capital Expenditures rose 3333.33% to $4000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $4000.0, marking a year-over-year decrease of 2000.0%. This contributed to the annual value of $6000.0 for FY2024, which is 6842.11% down from last year.
  • According to the latest figures from Q4 2024, NovaBay Pharmaceuticals' Capital Expenditures is $4000.0, which was up 3333.33% from $2000.0 recorded in Q1 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Capital Expenditures peaked at $80000.0 during Q3 2022, and registered a low of $1000.0 during Q3 2023.
  • For the 5-year period, NovaBay Pharmaceuticals' Capital Expenditures averaged around $14333.3, with its median value being $8000.0 (2021).
  • In the last 5 years, NovaBay Pharmaceuticals' Capital Expenditures skyrocketed by 37058.82% in 2022 and then crashed by 9875.0% in 2023.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Capital Expenditures stood at $21000.0 in 2020, then crashed by 61.9% to $8000.0 in 2021, then skyrocketed by 900.0% to $80000.0 in 2022, then crashed by 96.25% to $3000.0 in 2023, then surged by 33.33% to $4000.0 in 2024.
  • Its Capital Expenditures was $4000.0 in Q4 2024, compared to $2000.0 in Q1 2024 and $3000.0 in Q4 2023.